On November 12, 2024 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, reported an upcoming poster presentation at the 66th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, being hosted December 7 – 10, 2024 in San Diego, CA (Press release, In8bio, NOV 5, 2024, View Source [SID1234648174]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the ASH (Free ASH Whitepaper) 2024 presentation are as follows:

Title: INB-100: Pilot Study of Donor Derived, ex-vivo Expanded/Activated Gamma-Delta T cell Infusion Following Haploidentical Hematopoietic Stem-Cell Transplantation and Post-Transplant Cyclophosphamide

Presenter: Joseph McGuirk, DO, The University of Kansas Cancer Center
Abstract #: 4823
Session Name: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III
Date and Time: Monday, December 9, 2024, 6:00 PM – 8:00 PM PDT

The abstract will be available online and can be accessed via the conference websites at ASH (Free ASH Whitepaper) Annual Meeting Abstracts. Reprints of the poster will also be accessible on the Events & Presentations page of IN8bio’s website following the presentations.